Abbott Laboratories

NYSE ABT

Abbott Laboratories Revenue for the Trailing 12 Months (TTM) ending September 30, 2024: USD 41.22 B

Abbott Laboratories Revenue is USD 41.22 B for the Trailing 12 Months (TTM) ending September 30, 2024, a 3.15% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • Abbott Laboratories Revenue for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 39.96 B, a -11.26% change year over year.
  • Abbott Laboratories Revenue for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 45.03 B, a 6.43% change year over year.
  • Abbott Laboratories Revenue for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 42.31 B, a 31.31% change year over year.
  • Abbott Laboratories Revenue for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 32.22 B, a 2.76% change year over year.
Key data
Date Revenue Gross Profit Operating Income EBIT
Market news
Loading...
NYSE: ABT

Abbott Laboratories

CEO Mr. Robert B. Ford
IPO Date March 17, 1980
Location United States
Headquarters 100 Abbott Park Road
Employees 114,000
Sector Health Care
Industries
Description

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Similar companies

BMY

Bristol-Myers Squibb Company

USD 55.74

0.69%

LLY

Eli Lilly and Company

USD 744.91

-6.59%

MDT

Medtronic plc

USD 85.25

4.23%

JNJ

Johnson & Johnson

USD 144.75

0.19%

ABBV

AbbVie Inc.

USD 175.55

-0.67%

StockViz Staff

January 15, 2025

Any question? Send us an email